Ticker brief
IMVT IMMUNOVANT INC
Consumer, Non-cyclical · Biotechnology
last close
$38.79
1 day
+1.7%
14 days
+9.8%
mkt cap
$8.0B
signals 14d
10
authors 14d
7
Sentiment — last 14 days
daily mean sentiment, 2026-06-22 → 2026-06-29 · now -0.05 (−1 bearish … +1 bullish)
Who spoke7
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @Quantumup1 | C | -1.95 | 3 | +0.00 |
| @bioinvestor24 | A | +1.35 | 2 | +0.23 |
| @MarketMaestro1 | C | -1.27 | 1 | +0.45 |
| @bullishchart | C | +1.98 | 1 | +0.35 |
| @SteveDJacobs | C | -0.20 | 1 | +0.20 |
| @PersimmonTI | A | -0.32 | 1 | +0.35 |
| @CEOStockWatcher | C | · | 1 | -0.20 |
Recent signals10of 10 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-06-29 | @Quantumup1 | +0.00 | William Blair and Wedbush reiterate bullish VRDN views; Wedbush raises PT to $43 from $32. | +0.7% | tweet ↗ |
| 2026-06-29 | @Quantumup1 | +0.00 | UBS reiterates VRDN Buy $50 after Lumvoa approval and outlines TAM and launch expectations. | +0.7% | tweet ↗ |
| 2026-06-29 | @CEOStockWatcher | -0.20 | Five IMVT insiders sold $3M, including CTO's first-ever sale, after stock rose 53%. | +0.7% | tweet ↗ |
| 2026-06-29 | @Quantumup1 | +0.00 | Citizens reiterates VRDN Market Outperform $35 after FDA approval of Lumvoa. | +0.7% | tweet ↗ |
| 2026-06-28 | @bioinvestor24 | +0.25 | Expects big oncology and immunology deals and flags SYRE as more derisked for pharma buyers. | -0.2% | tweet ↗ |
| 2026-06-28 | @PersimmonTI | +0.35 | ROIV CEO says pharma calls about IMVT all the time. | -0.2% | tweet ↗ |
| 2026-06-27 | @SteveDJacobs | +0.20 | Minervini Trend Template screener lists 54 qualifying stocks. | -0.2% | tweet ↗ |
| 2026-06-24 | @bullishchart | +0.35 | Lists bio/health stocks hitting or near fresh highs with prices. | +1.5% | tweet ↗ |
| 2026-06-23 | @MarketMaestro1 | +0.45 | Calls IMVT a pretty good setup with chart. | +3.1% | tweet ↗ |
| 2026-06-22 | @bioinvestor24 | +0.20 | Framework for H2 2026 biotech M&A across immunology, oncology and obesity with multiple likely targets. | +1.8% | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.